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Abstract
Oligonucleotide arrays that detect single nucleotide polymorphisms
were used to generate genome-wide loss of heterozygosity (LOH) maps
from laser capture microdissected paraffin-embedded samples using as
little as 5 ng of DNA. The allele detection rate from such samples was
comparable with that obtained with standard amounts of DNA prepared
from frozen tissues. A novel informatics platform, dChipSNP, was used to
automate the definition of statistically valid regions of LOH, assign LOH
genotypes to prostate cancer samples, and organize by hierarchical clus-
tering prostate cancers based on the pattern of LOH. This organizational
strategy revealed apparently distinct genetic subsets of prostate cancer.
Introduction
Progress in treating human prostate cancer has been hampered by
the finding that histologically identical cancers exhibit widely variant
clinical behavior. It is anticipated that the development of molecular
taxonomies of prostate cancer will lead to the definition of unique
cancer subsets each marked by different clinical behavior, probabili-
ties of response to therapy, and cancer biology. Genomic efforts to
render such molecular classifications have included expression pro-
filing, proteome analysis, and comparative genomic hybridization.
These technologies typically require nonfixed cancer tissue and often
substantial quantities of cancer tissue. Ultimately, the widespread
clinical use of cancer classification methods will require technologies
capable of assaying small foci of cancerous tissue isolated from
paraffin-embedded tissues. Such technologies would be widely appli-
cable not only to routine clinical care but also to the retrospective
analysis of existing large paraffin-embedded sample collections ob-
tained during clinical trials or from large population-based cohorts.
Such data sets have largely been unstudied by current technologies.
Recessive oncogenic alterations typically lead to the biallelic inac-
tivation of tumor suppressor genes (1). Alterations such as homozy-
gous and heterozygous deletions or gene conversions are thought to be
among the most common genetic abnormalities in epithelial cancers
and the detection using LOH
5 analysis as being essential to the
discovery of the genes targeted by such events (2). Oligonucleotide
microarrays, capable of simultaneously determining the genotype of
1494 SNPs, have been used to map regions of LOH in small cell lung,
breast, bladder, and prostate cancer (3–7). In small cell lung cancer,
detection of regions of LOH using SNP arrays was shown to be
comparable with LOH detection using microsatellite markers but
required cancer cell purity of 90% (3). Similarly, LOH events
detected by SNP arrays in bladder cancer were consistent with mic-
rosatellite-detected events (6). Here, we show that using this technol-
ogy, the genotype of 1494 SNP alleles and genome-wide SNP-based
LOH maps can be obtained from laser capture microdissected samples
using as little as 5 ng of DNA obtained from paraffin-embedded
prostate cancer samples. Furthermore, we demonstrate the utility of a
new bioinformatic tool, dChipSNP, that automates the detection of
shared regions of LOH, allows for the hierarchical clustering of
cancers based on patterns of shared LOH, and allows the analysis
of the relationship between clinical parameters and LOH genotypes.
Using these methods, we show that subtypes of prostate cancer likely
arise through independent genetic pathways.
Materials and Methods
Prostate Cancer Samples and Clinical Data. Paraffin blocks along with
frozen SVs were available for 50 of a set of 52 prostate cancer samples, the
clinicopathological characteristics of which were described previously (8).
DNA Isolation. Half of each snap-frozen SV sample was fixed in 10%
buffered Formalin acetate, mounted in Tissue-Tek OCT, H&E stained, and
visualized by light microscopy to confirm the absence of cancer. Germ-line
DNA was prepared from the remainder by proteinase K digestion in SDS
buffer followed by two extractions in Tris-buffered phenol and chloroform
extraction. DNA was precipitated with 1/10
th volume of 3.5 M sodium acetate,
20 g of glycogen, and 2.5 volume of ethanol; washed in 70% ethanol twice;
and resuspended in 50 lo fT E .
Cancer DNA was obtained from the corresponding formaldehyde-fixed
paraffin-embedded prostatectomy cancer tissue. In brief, cancer epithelial cells
were identified by pathologists (M. Loda and M. Lechpammer) and retrieved
by LCM using an Arcturus PixCell II system (Mountain View, CA). Before
DNA extraction, LCM adhesive caps were visualized by light microscopy to
ensure 90% purity of epithelial cells. Cancer cells adhered to the LCM cap
were incubated in 50 l of digestion buffer (1% Tween 20, 1 mg/ml Proteinase
K, and 1  TE) overnight at 37°C, heated to 95°C for 10 min, and clarified by
centrifugation. DNA was quantified using the PicoGreen double-stranded
DNA Quantitation Kit using 2 l of DNA (Molecular Probes; P-11495). The
sample volume was split in two and subjected to SNP PCR amplification
according to the manufacturer’s protocol without further DNA purification.
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4781HuSNP PCR Amplification. Normal and cancer DNA was assayed using
a modification of the GeneChip HuSNP protocol (Affymetrix). The total
amount of input DNA was 120 ng for normal DNA and ranged from 4.4 to 47.1
ng (mean 26.4 ng) for cancer samples. For each genotype, 24 separate pools of
primer pairs (50–60 loci/pool) were added to 5 ng of normal DNA (or 0.37
pg to 2 ng of cancer DNA), 5 mM MgCl2, 0.5 mM deoxynucleoside triphos-
phates, 1.25 units of AmpliTaq Gold (Applied Biosystems), and supplied
buffer to a final reaction volume of 12.5 l/pool. PCR amplification was
carried out by denaturing at 95°C for 5 min, followed by 30 cycles of 95°C for
30 s, 58°C for 55 s, 72°C for 30 s, and a final extension of 7 min at 72°C. A
1-l sample of each PCR reaction pool was diluted separately in 999 lo f
H2O. From each of these dilutions, 2.5 l were removed and added to 0.8 M
biotinylated-T3 and 0.8 M biotinylated-T7 primers, 4 mM MgCl2, 0.4 mM
deoxynucleoside triphosphates, 2.5 units of AmpliTaq Gold, and the supplied
buffer for a final reaction volume of 25 l and reamplified by denaturing at
95°C for 8 min, followed by 40 cycles of 95°C for 30 s, 55°C for 90 s, 72°C
for 30 s, and a final extension of 7 min at 72°C. Successful PCR amplification
was confirmed by resolving 1.8 l of each pool in a 3% agarose gel. The 24
pools were combined and concentrated in a Microcon-YM10 centrifugal filter
(Millipore Corp.), and the final sample volume was adjusted to 60 l.
Hybridization, Washing, and Staining of the HU2K Oligonucleotide
Array. Thirty microliters of each sample were diluted in 3 M Tertramethyl-
ammouniom chloride, 2 nM oligonucleotide B1 (Affymetrix), 10 mM Tris-HCl
(pH 7.8), 0.01% Tween 20, 5 mM EDTA (pH 8.0), 100 g/ml herring sperm
DNA, and 5  Denhardt’s solution to a final volume of 135 l; heated to 95°C
for 10 min; and quenched on ice for 5 min. Samples were then hybridized to
the GeneChip HuSNP arrays (Affymetrix) overnight at 44°C at 40 rpm. Arrays
were washed twice with 6  SSPE, 0.01% Triton X-100 at 25°C, six times
with 4  SSPE, 0.01% Triton X-100, and stained with 500 lo f5 0g/ml
R-Phycoerythrin Streptavidin (Molecular Probes), 5 g/ml biotinylated-anti-
strepavidin antibody (Vector Labs), in 6  SSPE, 1  Denhardt’s solution, and
0.01% Triton X-100 for 30 min at 25°C. The arrays were washed six times
with 6  SSPE, 0.01% Triton X-100 at 25°C.
Scanning of the HuSNP Arrays and Assigning Genotypes. After stain-
ing of the arrays, the chips were scanned using a HP GeneArray Scanner
according to the GeneChip HuSNP Mapping Assay Manual (Affymetrix).
Genotypes were assigned by the Affymetrix GeneChip 4.0 software. For each
SNP, possible assigned genotypes included, homozygous for one allele (AA or
BB), heterozygous (AB). If the software could not make a genotype determi-
nation, possible assignments included: (a) AB_A (implying the genotype is
either AB or A); (b) AB_B (indicating the genotype is either AB or B); or (c)
“no signal.” The overall call rate was determined by the software to the number
of SNPs assigned to AB, AA, or BB divided by the total number of SNPs on
the microarrays (1494).
dChipSNP Analysis. The detailed statistical methods used to define re-
gions of LOH, assign LOH calls to each cancer, and cluster cancers based on
LOH are discussed and presented in full in a forthcoming study.
6 Briefly,
withina6M bwindow, a summary LOH score was derived across the entire
set of cancer/normal comparisons. The summary LOH score was compared
with the same score calculated from randomly permuted data. Regions of LOH
differing statistically in the actual data from that derived from the permuted
data were identified, and LOH assignments were made for each cancer based
on the calls made for specific SNP alleles within the bounded region. Hierar-
chical clustering based on LOH calls for these specific regions was carried out
as described previously (9).
Results and Discussion
Fifty-two prostate cancers, obtained at the time of radical prosta-
tectomy, were studied previously by expression profiling to predict
outcome after radical prostatectomy and detect the presence of an
expression-based metastatic signature (8, 10). For each cancer, paired
normal germ-line DNA was purified from pulverized unfixed frozen
SV obtained at the time of surgery. Sections of each SV were
examined histologically and found to be free of cancer.
The genotypes for 1494 SNPs were obtained using 120 ng of SV as
the normal DNA. As described previously, each SNP allele was
specifically amplified in 24 pooled highly multiplexed PCR reactions,
and after reamplification and labeling, the genotype of each allele was
determined by hybridization to the Hu2K SNP array (Affymetrix)
using the standard HuSNP protocol (as described in Lindblad-Toh,
2000). The rate of alleles successfully called (call rate) on the array is
an indicator of the quality of the DNA extraction, amplification, and
hybridization procedures and determined using the MAS software
(Affymetrix). The average call rate was 83.2% and ranged from 74.8
to 87.7% for assays run on the SV DNA. These results are consistent
with data published previously (Fig. 1).
In parallel, paraffin-embedded cancer blocks were retrieved for
each patient, sectioned, and reviewed by experienced prostate cancer
pathologists (M. Loda and M. Lechpammer). Pure populations of
malignant prostate epithelial cells were obtained using a Pixell LCM
instrument. For each cancer, cells were collected onto the LCM cap
until the cap was approximately half full. DNA was extracted in
SDS-proteinase K buffer and used without further purification. Half of
the LCM material, ranging from 4.6 to 47.1 ng of DNA, was then used
in the SNP amplification protocol without further adjustment. SNP
allele call rates in the cancer samples (81.6  3.3%) did not vary
significantly from that obtained with the normal DNA (Fig. 1). Thus,
the quality of SNP genotyping with LCM-captured DNA was com-
parable with that obtained with DNA extracted by standard methods
(Fig. 1). Using these methods, LOH detection was carried out in 50
available cancers from the original set of 52 cancers studied previ-
ously. The raw data are available on the Internet.
7
To enable the analysis of the SNP array data across multiple
cancer–normal comparisons, a new informatics platform known as
dChipSNP was developed. This platform is based on dChip, a bioin-
formatics package for oligonucleotide array-based expression analysis
(11, 12). The details of the statistical methods used in the dChipSNP
program for LOH determination are described in a forthcoming
study.
5 dChipSNP integrates publicly available SNP, gene, and cyto-
band mapping information with automated methods for detecting
statistically meaningful regions of LOH from a series of paired normal
and cancer SNP genotypes. dChipSNP is available for download on
the Internet.
8
Regions of LOH, usually arising as a result of either hemizygous
deletion or gene conversion events, are typically defined as stretches
6 M. Lin et al., submitted for publication.
7 Internet address: http://research.dfci.harvard.edu/sellerslab/datasets/index.html.
8 Internet address: http://www.dchip.org/.
Fig. 1. High-quality SNP array data obtained from laser capture microdissected cancer
cells. A, the average SNP allele call rate obtained from DNA extracted from flash-frozen
noncancerous tissue or from DNA extracted from laser capture microdissected paraform-
aldehyde fixed, paraffin-embedded cancer cells. B, the relationship between DNA quantity
and SNP call rate. DNA from cancer or normal samples (as described above) was
quantified by PicoGreen measurement. DNA (120 ng) from each normal SV sample and
50% of the total available cancer DNA were used in the standard HuSNP protocol.
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GENOME-WIDE LOH MAPPINGof chromosomal areas where all heterozygous and thereby informative
alleles are rendered homozygous in the cancer. The boundaries of
such regions of LOH are defined by either the presence of retained
heterozygous alleles, the ends of chromosomal arms, or the centro-
some. This classical definition assumes that all data points are com-
pletely accurate and that all polymorphic alleles are mapped correctly
within the genome. Array-based methods of SNP detection may have
a certain degree of inaccuracy (“noise”), and moreover, the precise
genome mapping of each SNP is still not completely stable. Thus,
“true” regions of LOH can be interrupted by apparently false positive
“retained” SNP alleles. Conversely, true regions of retention of het-
erozygosity may be interrupted by false LOH calls. To take these
concerns into consideration, a method for assessing the probability of
LOH within a given set of normal cancer comparisons was used where
within a sliding 6 Mb window, a summary LOH score was derived. To
determine whether the measured summary LOH scores exceed those
that might occur by chance alone, 1000 data sets were generated in
which the sample designation of cancer versus normal was randomly
permuted. Regions of deletion were identified where the summary
LOH score exceeded that found in the permuted data sets. A P-value,
corrected for multiple hypothesis testing, of 0.05 was used as the
cutoff (as described in detail in Lin et al.). The predicted region of
LOH was demarcated by dChipSNP. Fig. 2A shows the application of
this platform to this data set, specifically showing a demarcated region
of deletion predicted on chromosome 8 (8p21).
In this manner, seven regions of significant LOH were found in a
fully automated fashion, including 1p33–34, 3q27, 8p21, 10q23,
15q12 16q23–24, and 17p13 (Figs. 2, A and B and Supplemental Fig.
Fig. 2. SNP array-based LOH maps for 8p21
and 10q23. A, automated detection and demarca-
tion of the 8p21 region of LOH in prostate cancers
using dChipSNP. Each column represents one
tumor/normal pair. Along the far right, the position
and name of each SNP are shown. Where the
density of SNPs is too high to allow a full display
of all SNPs, hidden SNPs are indicated by small
blue dots. Additionally along the right within the
shaded gray box is the LOH score indicated as a
blue line and the P  0.05 threshold indicated as a
red line. Tumors in which there is LOH within the
8p21 region are identified and organized by hier-
archical clustering (left branch) as distinct from
tumors with definitively retained alleles within the
8p21 regions (right branch). There are no uninfor-
mative tumors for this region. Finally, clinical or
pathological information pertinent to each tumor is
indicated along the top (GS, Gleason Score;
CStage, Clinical Stage; PStage, Pathological Stage;
Cp Inv, Capsule invasion; SV Inv, SV invasion,
LN , lymph node metastases; Marg , surgical
margin positive; Fail PSA, failure after prostatec-
tomy; LV Inv, lymphatic vessel invasion; and risk,
prostate cancer risk group). B, automated detection
and demarcation of the 10q23 region of LOH.
dChipSNP precisely demarcates the area centered
over the PTEN tumor suppressor gene. Left panel,
a segment of the LOH plot for chromosome 10 (as
in Fig. 2A); however, only those tumors with LOH
are shown. dChipSNP allows an expanded zoom in
view, and this reveals that the segment of chromo-
some 10 identified precisely overlies the PTEN
tumor suppressor gene.
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GENOME-WIDE LOH MAPPING1, A–F). LOH in prostate cancer localized to 1p, 8p21, 10q23, 16q23,
and 17p13 have all been reported previously by multiple investigators,
with LOH of 8p21 being among the most frequently reported in
prostate cancer (Refs. 13–27 and reviewed in Ref. 28). This method-
ology, given sufficient overlapping alterations, might lead to en-
hanced localization of putative genes targeted within the regions of
LOH. The PTEN gene is thought to be the tumor suppressor gene
targeted by alterations in the 10q23 cytoband. The density of inform-
ative SNPs in this region, while relatively low, was nonetheless
sufficient to give a peak prediction of LOH that corresponded directly
with the physical location of PTEN (Fig. 2B). Together, the detection
of known regions of LOH and colocalization of a predicted peak with
a known cancer suppressor argue that microarray-based LOH detec-
tion and the automated statistical methods developed for analyzing
these data are robust.
Next, we sought to determine whether sample organization algo-
rithms, such as hierarchical clustering, could be applied to this data
set. Here, the direct use of the actual SNP allele data in clustering
algorithms, much as one would use expression array data, would lead
to sample organization based on the germ-line genetic similarities of
the individuals rather than on the genetic similarities of the cancer.
Moreover, LOH of the same chromosomal region can be marked by
completely different sets of heterozygous and thus informative SNPs
in distinct cancer–normal pairs. Thus, it is necessary to render the
SNP data for each cancer–normal pair into an LOH-based data set. To
this end, for each cancer–normal pair, a designation of LOH, retained
or uninformative, was made based on the actual genotype of the
heterozygous SNPs within the seven regions of significant LOH
identified above. Here, retention (RET) was defined as the presence of
an informative allele within the region of interest in which heterozy-
gosity was retained (RET) without any heterozygous alleles showing
LOH. In dChipSNP, these data can be output as specific tab delimited
data sets (see Supplemental Table 1). For purposes of display only, the
regions of LOH or retention for each cancer–normal pair are projected
as a heat map of blue or yellow using a 50% extension to the next
nearest heterozygous SNP. In certain instances, the heat map extend-
ing from an allele showing LOH extends into the region of LOH;
however, if the actual SNP allele is not within the demarcated region,
than the cancer is not designated as LOH for that region.
After such designation, one can cluster cancers based only on a
single region of LOH in the chromosome view (Fig. 2) or using all
regions of loss defined as significant in the whole genome view. In the
first instance, hierarchical clustering was driven by using the compar-
isons LOH-to-LOH, LOH-to-RET, and RET-to-RET. This resulted in
either two or three clusters of tumors for each region of LOH,
specifically a cluster with LOH, a cluster with retention, and a cluster
of uninformative tumor (Fig. 2A and Suppl. Fig. 1, A–F). This analysis
allows the automatic assignment of the genotype for this region to
each individual tumor and can be then used in further downstream
analysis pertinent to the specific region, e.g., we have looked for gene
expression signatures associated with specific regions of LOH by
using those tumors that are definitely scored as LOH and those that
are definitively scored as RET, while ignoring those that are uninfor-
mative in a given region.
For many human cancers, it is thought that there is a sequential
progression of accumulated genetic events, ultimately cumulating in a
metastatic cancer. In prostate cancer, it remains to be seen whether the
heterogeneous nature of the disease can be understood based on this
model wherein early genetic events would be then accompanied or not
accompanied by late genetic alterations, thus leading to differences in
the disease, or whether an alternative, but not mutually exclusive,
model in which distinct “parallel” sets of genetic alterations might
occur, leading to unique genetic cancer subtypes that have distinct
clinical behavior.
To determine whether genome-wide LOH mapping might provide
an answer to this question, hierarchical clustering was used to look for
separation or cosegregation of LOH events. In this analysis, clustering
was enacted using the seven regions of LOH passing the P  0.05
threshold. Again, each tumor was assigned a lost or retained desig-
nation based on SNP alleles within the boundaries of LOH. The
Fig. 3. Hierarchical clustering of prostate can-
cers based on LOH similarity. Each of the cancers
was assigned a designation of RET, LOH, or unin-
formative for the seven regions of LOH detected in
this data set. Hierarchical clustering of samples
without clustering of regions was undertaken using
the comparisons of LOH:LOH and LOH:RET,
whereas RET:RET and uninformative loci were
ignored. Tumor normal pairs are shown as
columns, whereas the indicated regions of LOH and
SNP alleles within them are shown as rows.
Regions of LOH are indicated by blue, although
regions of RET are indicated by yellow.
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GENOME-WIDE LOH MAPPINGcomparisons of LOH-to-LOH and LOH-to-RET were used, whereas
RET-to-RET was ignored. This allows clustering to be driven primar-
ily by the similarity or difference in a deletion rather than the simi-
larity in retention.
A number of cancers had either no informative alleles or did not
show LOH in any of the seven regions and thus were not clustered in
this analysis (single branches in Fig. 3. The clustering of tumors with
sufficient information revealed that samples were clustered into dis-
tinct branches and that these branches contained tumors enriched for
specific nonoverlapping regions of heterozygosity. These data suggest
the possibility that there are distinct genetic subsets of prostate cancer
that can be defined based on LOH analysis. Validation of this obser-
vation on higher density and thus more sensitive SNP arrays is an
important next step.
In summary, we provide a novel and robust tool for LOH detection.
This informatics package and the automated detection of LOH will be
a vital tool for the analysis of large SNP LOH data sets that will be
available on the second generation of SNP arrays where the cancer–
normal genotypes of 10,000 SNP alleles will be available.
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